Inj ruxience, 10 mg
Products billed under this code include Ruxience.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ruxience.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ruxience | Pfizer Inc | 00069-0238-01 | 10 | $57.92 |
| Ruxience | Pfizer Inc | 00069-0249-01 | 50 | $289.60 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5.792 | −$10.368 | 10 MG | Inj ruxience, 10 mg | v1, posted September 17, 2026 |
| 3Q26 | $16.16 | +$2.474 | 10 MG | Inj ruxience, 10 mg | v1, posted September 15, 2026 |
| 2Q26 | $13.686 | +$0.416 | 10 MG | Inj ruxience, 10 mg | v1, posted September 15, 2026 |
| 1Q26 | $13.27 | −$14.575 | 10 MG | Inj ruxience, 10 mg | v1, posted September 15, 2026 |
| 4Q25 | $27.845 | +$1.342 | 10 MG | Inj ruxience, 10 mg | v1, posted September 8, 2026 |
| 3Q25 | $26.503 | +$1.56 | 10 MG | Inj ruxience, 10 mg | v1, posted March 10, 2026 |
| 2Q25 | $24.943 | +$1.354 | 10 MG | Inj ruxience, 10 mg | v1, posted March 10, 2026 |
| 1Q25 | $23.589 | +$1.152 | 10 MG | Inj ruxience, 10 mg | v1, posted December 19, 2025 |
| 4Q24 | $22.437 | +$3.186 | 10 MG | Inj ruxience, 10 mg | v1, posted June 11, 2025 |
| 3Q24 | $19.251 | −$1.024 | 10 MG | Inj ruxience, 10 mg | v1, posted June 11, 2025 |
| 2Q24 | $20.275 | −$0.172 | 10 MG | Inj ruxience, 10 mg | v1, posted March 11, 2025 |
| 1Q24 | $20.447 | −$1.857 | 10 MG | Inj ruxience, 10 mg | v1, posted December 19, 2024 |
| 4Q23 | $22.304 | −$2.414 | 10 MG | Inj ruxience, 10 mg | v1, posted October 10, 2024 |
| 3Q23 | $24.718 | −$2.867 | 10 MG | Inj ruxience, 10 mg | v1, posted June 5, 2024 |
| 2Q23 | $27.585 | −$3.502 | 10 MG | Inj ruxience, 10 mg | v1, posted February 23, 2024 |
| 1Q23 | $31.087 | −$8.654 | 10 MG | Inj ruxience, 10 mg | v1, posted December 6, 2023 |
| 4Q22 | $39.741 | −$4.288 | 10 MG | Inj ruxience, 10 mg | v1, posted June 22, 2023 |
| 3Q22 | $44.029 | −$5.787 | 10 MG | Inj ruxience, 10 mg | v1, posted June 9, 2023 |
| 2Q22 | $49.816 | −$6.554 | 10 MG | Inj ruxience, 10 mg | v1, posted December 14, 2022 |
| 1Q22 | $56.37 | −$2.426 | 10 MG | Inj ruxience, 10 mg | v1, posted June 8, 2022 |
| 4Q21 | $58.796 | −$3.686 | 10 MG | Inj ruxience, 10 mg | v1, posted June 2, 2022 |
| 3Q21 | $62.482 | −$2.025 | 10 MG | Inj ruxience, 10 mg | v1, posted June 2, 2022 |
| 2Q21 | $64.507 | −$2.816 | 10 MG | Inj ruxience, 10 mg | v1, posted March 1, 2022 |
| 1Q21 | $67.323 | – | 10 MG | Inj ruxience, 10 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.